DE69227380D1 - Verfahren zur bestimmung und behandlung von alzheimer-krankheit - Google Patents

Verfahren zur bestimmung und behandlung von alzheimer-krankheit

Info

Publication number
DE69227380D1
DE69227380D1 DE69227380T DE69227380T DE69227380D1 DE 69227380 D1 DE69227380 D1 DE 69227380D1 DE 69227380 T DE69227380 T DE 69227380T DE 69227380 T DE69227380 T DE 69227380T DE 69227380 D1 DE69227380 D1 DE 69227380D1
Authority
DE
Germany
Prior art keywords
determining
alzheimer disease
treating alzheimer
treating
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69227380T
Other languages
English (en)
Other versions
DE69227380T2 (de
DE69227380T3 (de
Inventor
Colin Masters
Ashley Ian Bush
Konrad Beyreuther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alterity Therapeutics Ltd
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25644152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69227380(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Melbourne filed Critical University of Melbourne
Application granted granted Critical
Publication of DE69227380D1 publication Critical patent/DE69227380D1/de
Publication of DE69227380T2 publication Critical patent/DE69227380T2/de
Publication of DE69227380T3 publication Critical patent/DE69227380T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
DE69227380T 1991-11-12 1992-11-12 Verfahren zur bestimmung und behandlung von alzheimer-krankheit Expired - Lifetime DE69227380T3 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPK943891 1991-11-12
AU9438/91 1991-11-12
AU3374/92 1992-07-08
AUPL337492 1992-07-08
PCT/AU1992/000610 WO1993010459A1 (en) 1991-11-12 1992-11-12 A method for assaying and treating alzheimer's disease

Publications (3)

Publication Number Publication Date
DE69227380D1 true DE69227380D1 (de) 1998-11-26
DE69227380T2 DE69227380T2 (de) 1999-04-08
DE69227380T3 DE69227380T3 (de) 2007-01-11

Family

ID=25644152

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69227380T Expired - Lifetime DE69227380T3 (de) 1991-11-12 1992-11-12 Verfahren zur bestimmung und behandlung von alzheimer-krankheit

Country Status (7)

Country Link
US (2) US5705401A (de)
EP (1) EP0613560B2 (de)
JP (1) JP3277211B2 (de)
AU (1) AU669493B2 (de)
CA (1) CA2123211C (de)
DE (1) DE69227380T3 (de)
WO (1) WO1993010459A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3277211B2 (ja) * 1991-11-12 2002-04-22 プラナ・バイオテクノロジー・リミテッド アルツハイマー病の試験方法と治療方法
EP1060750B1 (de) * 1993-03-29 2005-12-07 Queen's University At Kingston Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable Salze zur Behandlung von Amyloidosis
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5872101A (en) * 1995-01-06 1999-02-16 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5789426A (en) * 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
DE19518845A1 (de) * 1995-05-23 1996-11-28 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Phytinsäure
JPH0925234A (ja) * 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
AU6887996A (en) * 1995-09-01 1997-04-01 Washington University School Of Medicine Method of reducing neurotoxic injury with zinc chelators
IL115465A0 (en) * 1995-09-29 1995-12-31 Yeda Res & Dev Assay for the diagnosis of dementia
AUPN649395A0 (en) * 1995-11-10 1995-12-07 Ramsay Health Care Pty Ltd A method for diagnosing alzheimer's disease
GB9610829D0 (en) * 1996-05-23 1996-07-31 Medical Res Council Screening of agents for treatment of azlheimers disease
JP2000516606A (ja) * 1996-08-13 2000-12-12 ピー・エヌ・ゲロリマトス・ソシエテ・アノニム アルツハイマー病の処置用医薬組成物の製造におけるキレート化剤クリオキノールの使用
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
WO1998040071A1 (en) * 1997-03-11 1998-09-17 The General Hospital Corporation Identification of agents for use in the treatment of alzheimer's disease
ES2177024T3 (es) 1997-08-21 2002-12-01 Gerolymatos P N Sa Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
US5980914A (en) * 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
WO1999045139A1 (en) 1998-03-05 1999-09-10 Board Of Regents, The University Of Texas System Diagnostic assay for late-onset alzheimer's disease
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
TR200101892T2 (tr) 1999-01-07 2001-11-21 P.N. Gerolymatos S.A. Hafıza bozukluklarının tedavisi veya önlenmesi için fankuinonun kullanımı.
DE19909357A1 (de) * 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
US6087118A (en) * 1999-03-04 2000-07-11 Bristol-Myers Squibb Company Method for diagnosing alzheimer's disease
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US6608042B2 (en) * 2000-03-28 2003-08-19 Aventis Pharma, S.A. Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
WO2002005634A2 (en) 2000-07-13 2002-01-24 University Of South Florida Transgenic animal and methods
US20020172676A1 (en) * 2001-05-16 2002-11-21 George Jackowski Method of treatment of alzheimer's disease and device therefor
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7517868B2 (en) * 2004-07-19 2009-04-14 Ip-6 Research Inc Phytic citrate compounds and process for preparing the same
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
DE102005037298A1 (de) * 2005-08-08 2007-03-08 Christine Jaschek Verwendung von Kalium-, Magnesium-, Calcium- und Zink-Elektrolyten zur Behandlung des Elementemangel- und Austrocknungssyndroms Alzheimer und anderer Demenzen
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
DK1954718T3 (en) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
EP2808032B1 (de) * 2005-12-12 2018-08-01 AC Immune S.A. A beta spezifische monoklonale antikörper mit therapeutischen eigenschaften
WO2007125385A2 (en) 2005-12-22 2007-11-08 Neurochem (International) Limited Treatment of renal disorders, diabetic nephopathy and dyslipidemias
CA2657681C (en) * 2006-07-14 2019-03-19 Ac Immune S.A. Humanized antibodies against beta amyloid protein
BRPI0717794B8 (pt) 2006-10-12 2021-05-25 Bellus Health International Ltd composto e composição farmacêutica de ácido 3-amino-1-propanosulfônico
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100203044A1 (en) * 2006-12-22 2010-08-12 Anatoly Nikolaev Dr6 antagonists and uses thereof in treating neurological disorders
US20100311767A1 (en) * 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
ES2529174T3 (es) * 2007-06-12 2015-02-17 Ac Immune S.A. Anticuerpos humanizados para amiloide beta
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
ES2609918T3 (es) * 2007-10-05 2017-04-25 Genentech, Inc. Uso de anticuerpo anti-amiloide beta en enfermedades oculares
EP2586795B1 (de) * 2007-10-05 2018-05-16 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten
CN102124336A (zh) * 2008-06-12 2011-07-13 健泰科生物技术公司 用于筛选抑制神经变性的化合物的方法
BRPI0921837A2 (pt) 2008-11-25 2016-01-12 Biogen Idec Inc anticorpos isolados ou fragmentos de antígeno de ligação dos mesmos que podem se ligar especificamente a um polipeptídio dr6, métodos in vitro de promover a sobrevivência de uma célula do sistema nervoso, usos de um antagonista dr6 e métodos in vitro de inibir a ligação de dr6 com p75
JP2013510871A (ja) * 2009-11-12 2013-03-28 ジェネンテック， インコーポレイテッド 樹状突起棘の密度を促す方法
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
EP2598882B1 (de) 2010-07-30 2017-07-26 AC Immune S.A. Sichere und funktionelle humanisierte antikörper für die verwendung in der behandlung von einer amyloidose
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
WO2012027794A2 (en) * 2010-09-01 2012-03-08 The Mental Health Research Institute Of Victoria Method of treatment and agents useful for same
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
WO2012142666A1 (en) * 2011-04-19 2012-10-26 The Mental Health Research Institute Of Victoria Method of modulating amine oxidase activity and agents useful for same
EP2717886B1 (de) * 2011-06-08 2021-09-01 Chelation Partners Incorporated Metallchelatierende gemische und verfahren zur regulierung des wachstums oder der aktivitäten einer lebenden zelle oder eines organismus
US10279054B2 (en) * 2013-07-09 2019-05-07 Mayo Foundation For Medical Education And Research Pet imaging of zinc transport
EP3039431A4 (de) * 2013-08-27 2017-05-03 CRC for Mental Health Ltd. Verfahren zur identifizierung von biomarkern neurologischer krankheiten und diagnose von neurologischen krankheiten
US20210071183A1 (en) * 2018-02-26 2021-03-11 The Trustees Of Columbia University In The City Of New York Zinc associated treatment for and diagnosis of cachexia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4419365A (en) * 1981-12-21 1983-12-06 Ciba-Geigy Corporation Method of treating Alzheimer's disease
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4837219A (en) * 1987-11-05 1989-06-06 Jeffrey Hutterer Medication for Alzheimer's disease
US4837164A (en) * 1988-04-27 1989-06-06 Bionix Corporation Methods for diagonosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
JPH05507470A (ja) * 1990-04-12 1993-10-28 アクゾ・エヌ・ヴエー Ｍｃａ２８ａ３２によって認識される抗原ｃｔａａ２８ａ３２
JPH05506990A (ja) * 1990-04-24 1993-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテアーゼ　ネキシン―２の精製、検出、及び使用方法
AU8215391A (en) * 1990-06-29 1992-01-23 Case Western Reserve University Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
AU643835B2 (en) * 1990-08-17 1993-11-25 Boston University Proteases causing abnormal degradation of amyloid beta-protein precursor
JPH04126095A (ja) * 1990-09-14 1992-04-27 Asahi Chem Ind Co Ltd 新規モノクローナル抗体及びそれを産生するハイブリドーマ
CA2372251A1 (en) * 1991-01-21 1992-08-06 Michael John Mullan Test and model for alzheimer's disease
JPH04252954A (ja) * 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパクの測定方法、試薬及びキット
JPH04252955A (ja) * 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd 蛋白質の測定方法、試薬及びキット
JPH04252956A (ja) * 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパク質の測定方法、試薬及びキット
JP3277211B2 (ja) * 1991-11-12 2002-04-22 プラナ・バイオテクノロジー・リミテッド アルツハイマー病の試験方法と治療方法
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same

Also Published As

Publication number Publication date
CA2123211A1 (en) 1993-05-27
JP3277211B2 (ja) 2002-04-22
JPH07503316A (ja) 1995-04-06
WO1993010459A1 (en) 1993-05-27
CA2123211C (en) 2008-09-16
AU669493B2 (en) 1996-06-13
EP0613560B1 (de) 1998-10-21
DE69227380T2 (de) 1999-04-08
EP0613560A4 (de) 1995-05-17
EP0613560A1 (de) 1994-09-07
DE69227380T3 (de) 2007-01-11
US5705401A (en) 1998-01-06
US20040265847A1 (en) 2004-12-30
EP0613560B2 (de) 2006-06-21
AU2926392A (en) 1993-06-15

Similar Documents

Publication Publication Date Title
DE69227380T2 (de) Verfahren zur bestimmung und behandlung von alzheimer-krankheit
ATE230606T1 (de) Verfahren zur vorbeugung und behandlung von allergien
DE69838789D1 (de) Verfahren zur behandlung oder prävention der alzheimerischen krankheit
DE696923T1 (de) Verfahren zur behandlung endo-ostealer materialen
DE69112480D1 (de) Verfahren und Vorrichtung zur Behandlung von medizinischen Abfallstoffen.
DE69331469D1 (de) Verfahren zur behandlung von abfällen
DE69218202T2 (de) Verfahren zur behandlung von fluoroaluminosilikatgläsern
DE69222735D1 (de) Zusammensetzung und Verfahren zur Behandlung von Kühlwasser
DE3888205D1 (de) Verfahren zur behandlung von lungenaffektionen und zubereitungen dafür.
DE69123519D1 (de) Verfahren und Vorrichtung zur Bestimmung von Ionen
ATE225185T1 (de) Verfahren zur behandlung von allergischem asthma
DE69115921D1 (de) Verfahren zur behandlung und verwendung von abfallstoffen
DE69231592T2 (de) Verfahren und zusammensetzungen zur behandlung von malaria und anderen erkrankungen
DE69228054D1 (de) Orthomolekulares verfahren zur behandlung von sichelzellanämie
DE69626311D1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
ATA66096A (de) Verfahren und vorrichtung zur elektrolytischen behandlung von durchlaufendem gut
DE69006509D1 (de) Verfahren zur behandlung von häuten.
DE69429341D1 (de) Verfahren zur behandlung von flüssigkeiten
DE69634207D1 (de) Verfahren zur behandlung von böden und/oder schüttgütern
DE69214139T2 (de) Verfahren zur behandlung von mit feuchtigkeit enthaltenden feinkohlen
ATA171489A (de) Verfahren zur behandlung von abfallstoffen
ATA21789A (de) Verfahren zur behandlung von abfallstoffen
DE69104438T2 (de) Verfahren zur bestimmung von glukose-6-phosphat und zusammensetzung dafür.
ATA315888A (de) Verfahren zur behandlung von abfallstoffen
DE68911922T2 (de) Vorrichtung und verfahren zur behandlung von bodenbelägen.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: PRANA BIOTECHNOLOGY LTD., SOUTH MELBOURNE, VICTORI

8366 Restricted maintained after opposition proceedings